GW Pharmaceuticals Seeks FDA Approval For Cannabis Based Epidiolex
Children afflicted with Dravet Syndrome, a rare form of epilepsy, have been effectively treated with a cannabis-based drug, Epidiolex, containing cannabinoids, the GW Pharmaceuticals announced Monday. Investors snapped up shares of the little-known firm, effectively doubling the company’s market value overnight.
GW Pharmaceuticals are seeking approval for Epidiolex from U.S. Food and Drug Administration
Analysts expect GW Pharmaceuticals Epidiolex to cost $2,500 to $5,000 a month, which would be more expensive than some of the medical marijuana products, which cost from about $100 to more than $1,000 per month. However, Epidiolex might be covered by insurance, unlike the other products.
GW Pharmaceuticals may be a new play for investors, but the Salisbury, England-based company is widely known in the cannabis world, where it enjoys the respect if not the love of many in the legalization movement.
GW Pharmaceuticals , which has been around since 1998 and public since 2001, has...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin